Pharma major Lupin Ltd today said it has received final approval from the US health regulator for its generic version of Dovonex scalp solution used in treatment of psoriasis of scalp.
The approval by the US Food and Drug Administration (USFDA) to Lupin's calcipotriene topical solution is for strength of 0.005 per cent (scalp solution), the company said in a statement.
It is the generic equivalent of Dovonex scalp solution of Lep Pharmaceutical Products Ltd. It is used for topical treatment of chronic, moderately severe psoriasis of the scalp.
Citing IMS data, the company said Calcipotriene topical solution had annual sales of USD 5.9 million in the US till October this year.
Shares of Lupin Ltd ended 0.67 per cent higher at Rs 880.85 apiece on the BSE today.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)